Insider Transaction Report for Adaptive Biotechnologies Corp

This filing details a transaction by Susan Bobulsky, Chief Commercial Officer, MRD of Adaptive Biotechnologies Corp. On July 16, 2026, Ms. Bobulsky sold 5,000 shares of common stock at a price of $23.00 per share, resulting in a post-transaction ownership of 401,288 shares. This transaction was executed under a Rule 10b5-1 trading plan established on December 16, 2025. The filing is an SEC Form 4, reporting a change in beneficial ownership.